Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN versus ERYC 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN versus ERYC 125.
BIAXIN vs ERYC 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic